slides · global inventory
Title
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 303,780
Current window 38,911-38,940
Pages 10,126
Rows per page 30
Component
38,911-38,940 of 303,780
11
The slide uses a process diagram to show disease progression and three columns to define the specific conditions.Hepion Pharmaceuticals | Results Presentation Deck | 34 slides · Hepion Pharmaceuticals
Pitch deck Investor relations 2 hits
12
Hepion Pharmaceuticals | Results Presentation Deck | 34 slidesHepion Pharmaceuticals | Results Presentation Deck | 34 slides · Hepion Pharmaceuticals
Pitch deck Investor relations 2 hits
14
The slide uses a process-style arrow diagram to represent the sequence of Phase 1 study components.Hepion Pharmaceuticals | Results Presentation Deck | 34 slides · Hepion Pharmaceuticals
Pitch deck Investor relations 2 hits
17
The slide presents clinical trial outcomes for a pharmaceutical asset.Hepion Pharmaceuticals | Results Presentation Deck | 34 slides · Hepion Pharmaceuticals
Pitch deck Investor relations 2 hits
19
The diagram uses a brain visualization to represent the integration of AI technologies into the central AI-POWR platform.Hepion Pharmaceuticals | Results Presentation Deck | 34 slides · Hepion Pharmaceuticals
Pitch deck Investor relations 2 hits
20
Uses a funnel diagram to represent the filtering of patient data into responders and non-responders.Hepion Pharmaceuticals | Results Presentation Deck | 34 slides · Hepion Pharmaceuticals
Pitch deck Investor relations 2 hits
21
The slide uses a network graph to visualize gene interactions, categorized by color-coded functional groups.Hepion Pharmaceuticals | Results Presentation Deck | 34 slides · Hepion Pharmaceuticals
Pitch deck Investor relations 2 hits
31
Uses a Venn diagram to show the intersection of three core strategic pillars.Hepion Pharmaceuticals | Results Presentation Deck | 34 slides · Hepion Pharmaceuticals
Pitch deck Investor relations 2 hits
25
The slide provides a reconciliation of non-GAAP financial measures as required by regulatory standards.IBM | Results Presentation Deck | 29 slides · IBM
Conference presentation Investor relations Beat · Action2 hits
26
The slide provides a detailed breakdown of revenue growth metrics across various business units, highlighting the impact of currency adjustments.IBM | Results Presentation Deck | 29 slides · IBM
Conference presentation Investor relations Beat · Action2 hits
27
The table breaks down SG&A, RD&E, and Operating expense & other income into GAAP, Non-GAAP Adjustments, and Operating (Non-GAAP) columns.IBM | Results Presentation Deck | 29 slides · IBM
Conference presentation Investor relations Beat · Action2 hits
28
The table details adjustments for acquisition, retirement, tax reform, and Kyndryl-related impacts.IBM | Results Presentation Deck | 29 slides · IBM
Conference presentation Investor relations Beat · Action2 hits
05
The slide uses a stylized graphic of a person transitioning into digital pixels, likely representing digital transformation or cybersecurity.IGI | IPO Presentation Deck | 23 slides · IGI
Regulatory filing Investment bank 2 hits
07
Includes a stylized portrait with a pixel-dispersion effect.IGI | IPO Presentation Deck | 23 slides · IGI
Regulatory filing Investment bank 2 hits
15
The slide uses a gauge chart for the risk score and two tables for vulnerability categorization.IGI | IPO Presentation Deck | 23 slides · IGI
Regulatory filing Investment bank Beat · Product2 hits
01
Includes company logo, presenter names, date, and corporate tagline.Immatics | Results Presentation Deck | 25 slides · Immatics
Conference presentation Investor relations Beat · Problem2 hits
03
Includes histological images of PRAME expression and a table of prevalence by indication.Immatics | Results Presentation Deck | 25 slides · Immatics
Conference presentation Investor relations Beat · Problem2 hits
04
The slide uses a process flow diagram to show the progression of clinical trial cohorts.Immatics | Results Presentation Deck | 25 slides · Immatics
Conference presentation Investor relations Beat · Problem2 hits
05
The slide uses a process flow diagram to illustrate trial cohorts. Cohorts B and C are greyed out, indicating they are not the focus of this specific update.Immatics | Results Presentation Deck | 25 slides · Immatics
Conference presentation Investor relations Beat · Problem2 hits
06
The slide uses a before-after framework to contrast the focus areas of two clinical trial phases, followed by a numbered list of specific improvements.Immatics | Results Presentation Deck | 25 slides · Immatics
Conference presentation Investor relations Beat · AgitateLoop · Before After2 hits
09
Data cut-off date is 06-Sept-2022. Includes footnotes regarding patient outcomes and definitions.Immatics | Results Presentation Deck | 25 slides · Immatics
Conference presentation Investor relations Beat · SolutionLoop · Before After2 hits
10
Data cut-off 06-Sept-2022. Footnotes define ORR and cORR criteria.Immatics | Results Presentation Deck | 25 slides · Immatics
Conference presentation Investor relations Beat · SolutionLoop · Before After2 hits
11
The slide uses waterfall charts to visualize clinical trial efficacy across various solid tumor types.Immatics | Results Presentation Deck | 25 slides · Immatics
Conference presentation Investor relations Beat · SolutionLoop · Before After2 hits
12
Clinical trial data visualization using spider plots (spaghetti plots) to track individual patient tumor burden changes.Immatics | Results Presentation Deck | 25 slides · Immatics
Conference presentation Investor relations Beat · SolutionLoop · Before After2 hits
13
Includes longitudinal persistence data, peak frequency comparison, and tumor infiltration correlation with clinical response (PD/SD vs PR/cPR).Immatics | Results Presentation Deck | 25 slides · Immatics
Conference presentation Investor relations Beat · SolutionLoop · Before After2 hits
16
The table calculates the addressable patient population by filtering total incidence down to R/R incidence, then applying PRAME positivity and HLA-A*02:01+ prevalence.Immatics | Results Presentation Deck | 25 slides · Immatics
Conference presentation Investor relations Beat · SolutionLoop · Quick Win Big Bet2 hits
17
Immatics | Results Presentation Deck | 25 slidesImmatics | Results Presentation Deck | 25 slides · Immatics
Conference presentation Investor relations Beat · SolutionLoop · Quick Win Big Bet2 hits
18
The slide uses a process flow diagram to illustrate clinical trial progression.Immatics | Results Presentation Deck | 25 slides · Immatics
Conference presentation Investor relations Loop · Quick Win Big Bet2 hits
19
The slide uses maps to visually represent the geographic distribution of clinical trial sites.Immatics | Results Presentation Deck | 25 slides · Immatics
Conference presentation Investor relations 2 hits
21
The slide uses box plots to compare current vs prior manufacturing processes across three key metrics: % CD8+ cells, % transduction, and peak T cell frequency.Immatics | Results Presentation Deck | 25 slides · Immatics
Conference presentation Investor relations 2 hits